PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of pediatricsLink to Publisher's site
 
Pediatrics. Jun 2012; 129(6): e1382–e1387.
PMCID: PMC3362900
Lipid Profiles of Children With Down Syndrome Compared With Their Siblings
Tahira Adelekan, MD,corresponding authora Sheela Magge, MD, MSCE,bc Justine Shults, PhD,d Virginia Stallings, MD,ce and Nicolas Stettler, MD, MSCEcdef
Divisions of aChild Development, Rehabilitation and Metabolic Diseases,
bEndocrinology and Diabetes, and
eGastroenterology, Hepatology and Nutrition, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania;
cDepartment of Pediatrics,
dCenter for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; and
fExponent, Inc, Menlo Park, California
corresponding authorCorresponding author.
Address correspondence to Tahira Adelekan, MD, The Children’s Hospital of Philadelphia, 3550 Market St, 3rd Floor, Philadelphia, PA 19104. E-mail: adelekan/at/email.chop.edu
Accepted January 25, 2012.
OBJECTIVES:
Our objective was to compare serum lipid profiles, total cholesterol (TC), low-density lipoprotein (LDL), triglycerides (TG), and high-density lipoprotein (HDL) between children with Down syndrome (DS) and their non-DS siblings. We hypothesized that the children with DS would have higher TC, LDL, and TG and lower HDL. The secondary aim was to explore if the difference in lipid profiles could be explained by differences in weight status.
METHODS:
This was a cross-sectional study. Fasting lipid profile was obtained from 27 children with DS and 31 siblings between 4 and 10 years of age with no severe comorbidities (heart disease, cancer, hypothyroidism, diabetes, or obesity). BMI was calculated and BMI z scores were used to account for differences in BMI throughout childhood.
RESULTS:
Children with DS had higher TC (difference, 11.2 mg/dL; 95% confidence interval: 2.5–19.9; P = .01), LDL (12.8 mg/dL; 7.2–18.4; P < .001), TG (33.6 mg/dL; 11.1–56.1; P = .003), and lower HDL (−7.6 mg/dL; −12.1 to −3.0; P = .001) after adjustment for race, gender, age, and ethnicity. Results remained significant after additional adjustment for BMI z score: TC (14.9 mg/dL; 4.9–24.9; P = .003), LDL (16.6 mg/dL; 10.1–23.2; P < .001), TG (32.7 mg/dL; 7.7–57.7; P = .01), and lower HDL (−6.4 mg/dL; −12.2 to −0.7; P = .03).
CONCLUSIONS:
Children with DS have less favorable lipid profiles than their siblings independent of weight status. These findings may have important implications for the screening and treatment of this large population at increased risk for ischemic heart disease.
KEY WORDS: hypercholesterolemia, Down Syndrome, pediatrics, obesity, prevention
What’s Known on This Subject:
Some researchers have suggested that individuals with Down syndrome (DS) are protected from atherosclerotic disease; however, recent data from 2 large cohort studies of individuals with DS are significant for increased mortality from ischemic heart disease and cerebrovascular disease.
What This Study Adds:
This study compares lipid profiles among children with DS and their siblings, highlighting the presence of a less favorable lipid profile in this high-risk population.
Down syndrome (DS) is one of the most common causes of developmental disability in the United States with a prevalence of 1 of every 691 live births.1 Persons born with DS are at increased risk for various health conditions, including thyroid disease, leukemia, congenital heart defects, gastrointestinal tract abnormalities, obesity, and diabetes mellitus.2 Despite this increased risk of chronic disease, life expectancy for individuals with DS has continued to improve with an estimated mean survival approaching 60 years of age.3 Increasing life expectancy along with an elevated risk of obesity and diabetes mellitus in individuals with DS, raise concerns about long-term health, in particular, atherosclerotic cardiovascular disease. Obesity and insulin resistance, which are common among individuals with DS, are associated with unfavorable (more atherogenic) lipid profiles, characterized by high triglycerides (TGs) and low high-density lipoprotein (HDL) cholesterol. Previous studies comparing lipid and lipoprotein concentrations in individuals with DS with individuals without DS have produced conflicting results.48 Additionally, it is unclear if individuals with DS have a particularly atherogenic lipid profile before developing obesity and diabetes.
Historically, individuals with DS were considered protected from atherosclerotic disease and, in fact, some researchers had proposed DS as an “atheroma-free” model of disease.4 Results of postmortem studies that found individuals with DS to have no atherosclerotic plaques, decreased frequency of arteriosclerosis, or decreased total area of raised lesions compared with non-DS controls are cited in the literature.4,9,10 However, there are conflicting reports that do not support describing DS as an atheroma-free model of disease. In examining autopsy material of institutionalized children <21 years of age with intellectual disability (ID), slightly more atherosclerosis was found in the coronary arteries and aortas of persons with DS in comparison with other residents with ID.11 Another study found fatty streaks and early fibromusculoelastic lesions in aortic segment autopsy material obtained from both the DS and control group, concluding that there was no decrease in prevalence of preatherosclerotic lesions in persons with DS compared with a control group that comprised persons with ID but without DS.12
Recent data from 2 large epidemiological studies of individuals with DS suggest that they may actually have an increased risk of mortality from ischemic heart disease and cerebrovascular disease compared with the general population.13,14 In 1 study of >4800 individuals from Sweden and Denmark, individuals with DS were found to have a 3.9-fold increased incidence of mortality due to ischemic heart disease. The authors of the study acknowledged that participants were selected through a hospital-based registry and may constitute a population with a greater risk for mortality.13 However, another epidemiological study of >14 000 individuals in California found a similar 4.3-fold increased incidence of mortality due to ischemic heart disease. In this study, participants were selected from a state department of developmental services registry.14
The aim of this study was to compare lipid profiles of nonobese, nondiabetic children with DS with their non-DS siblings to assess if DS is associated with an unfavorable lipid profile, independent of weight status. Because lipid profile is strongly associated with genetic and lifestyle factors, this sibling design is particularly useful to investigate the effect of DS on lipids, while reducing the between-group difference in familial variables. We hypothesized that children with DS would have higher total cholesterol (TC), higher low-density lipoprotein (LDL) cholesterol, higher TG, and lower HDL cholesterol compared with sibling controls. Additionally, we expected the DS group, even if nonobese, to have a greater BMI; therefore, the secondary aim of the study was to determine if differences in lipid profiles were mediated by BMI.
Participants
This cross-sectional study used participants from a 3-year prospective cohort study of growth and changes in body composition in children with DS and their siblings. Thirty-six families were recruited from the Philadelphia metropolitan area through physician referrals and information circulated to local DS parent groups. Families who had 1 child with DS and 1 child without DS were screened by telephone for eligibility. Inclusion criteria for the larger cohort study were as follows: (1) participants between 4 and 10 years of age, (2) prepubertal, (3) BMI below the 95th percentile for age and gender,15 based on parental telephone report of subject’s weight and height. For the current study, participants at or above the 95th BMI-for-age percentile when they presented at the study visit were also excluded. Children <4 years were excluded secondary to concerns about compliance with some of the measurements of the larger cohort study and children >10 years were excluded in an effort to limit the sample to prepubertal children. The following conditions were used as exclusion criteria: (1) history of congenital cardiac defect requiring open heart surgery; (2) history of intestinal anomalies requiring bowel resection and/or ongoing medical intervention; (3) history of hypothyroidism requiring medication or other chronic conditions known to affect energy balance or growth (including diabetes); and (4) history of cancer. If >1 sibling met eligibility criteria, the caregiver selected one to participate based on the child’s interest. Written informed consent from parent/guardian and assent from participants were obtained, and all procedures were reviewed and approved by the Institutional Review Board at The Children’s Hospital of Philadelphia.
Procedures
Demographic information was obtained via questionnaire during the families’ initial visit to the Clinical and Translational Research Center at The Children’s Hospital of Philadelphia. Anthropometric measurements were also obtained at the Clinical and Translational Research Center. Participants were weighed without shoes, wearing a light-weight gown on a daily calibrated Scaletronix digital scale (Scaletronix, White Plains, NY). Standing height was obtained via wall-mounted stadiometer (Holtain, Inc, Crymych, UK). Weight and height were measured in triplicate by a trained anthropometrist with the use of research-standard methods.16 All participants were measured by 1 single highly trained anthropometrist whose reliability was regularly assessed. BMI, defined as weight in kilograms divided by height in meters squared, was calculated. Because BMI varies with age and differs by gender, BMI z score was calculated by using age-, race-, and gender-specific BMI reference data.17
After a 12-hour supervised inpatient overnight fast with 24-hour nursing staff present, blood samples were drawn for TC, direct HDL, and TG. TC and TG levels were analyzed by the colorimetric method, with a reportable dynamic range of 50 to 325 mg/dL for cholesterol and 10 to 525 mg/dL for triglycerides. HDL was quantitatively measured by using a 2-point rate analysis via spectrophotometer with a reportable dynamic range of 3 to 110 mg/dL. LDL cholesterol was calculated by using the Friedewald equation.18
Statistical Analysis
Descriptive analyses were performed. Mean TC, LDL, HDL, and TG values were then analyzed for the 2 groups and compared by using generalized estimating equations (GEEs).
GEEs were implemented by using the xtgee procedure in Stata software (version 7.0; Stata Corp., College Station, TX). GEE extends linear regression and logistic regression to nonindependent data by specifying a working correlation structure that describes the pattern of association among the nonindependent measurements, in addition to the usual linear or logistic model for the expected value of the outcome variable. GEE was used to account for a lack of independence between the 2 groups and to adjust for confounding variables of age, gender, race, and ethnicity. The association of DS status with TC, HDL, LDL, and TG level was first analyzed unadjusted, then adjusting for confounding variables. To determine if BMI mediated any difference in lipid profile variables between the 2 groups, adjusted analyses were then performed with additional adjustment for BMI z score. The goal was to assess differences in TC, HDL, LDL, and TG between children with DS and the sibling control group, to adjust for potentially confounding variables, and to determine whether BMI mediated the observed difference. All analyses were performed by using Stata software and a P value of <.05 was accepted as statistically significant.
Of the 36 children with DS enrolled in the study, one was excluded secondary to a new diagnosis of hypothyroidism requiring treatment with hormone replacement therapy. Of the 36 siblings enrolled, 3 refused phlebotomy; therefore, no lipid samples were available. In addition, 8 subjects with DS and 2 control subjects were excluded because their BMI for age was at or above the 95th percentile at the measurement visit. Therefore, data were analyzed for 27 children with DS and 31 sibling controls. Descriptive information on study participants is reported in Table 1, including height and weight percentile ranges on DS growth curves for the children with DS.19 As expected, the children in the DS group were shorter and had higher BMI z scores compared with the sibling group.
TABLE 1
TABLE 1
Descriptive Characteristics (± SD) of Study Participants
Mean TC, LDL, TG, and HDL values for the DS group and the sibling groups are reported in Table 1. None of the lipid profiles obtained had any immediate clinical implications requiring medical or nutritional intervention. Mean TC, LDL, and TG levels were higher in the DS group than the sibling control group, and HDL levels were lower, although these differences were not statistically significant in the unadjusted analysis for TC and LDL. Unadjusted and adjusted analyses of the difference in mean lipid values between the study groups are presented in Table 2. Potentially confounding variables (gender, age, race, and ethnicity), identified a priori, were used to adjust differences in lipid levels. The differences in lipid concentrations were essentially unchanged after additional adjustment for BMIz (Table 2).
TABLE 2
TABLE 2
Mean Differences (95% CI) in Lipid Profile Variables Between Subjects With Down Syndrome and Their Siblings (Reference Group)
Results from this study suggest that the lipid profile of nonobese prepubertal children with DS is less favorable than that of their siblings, with higher concentrations of TC, LDL, and TG and lower concentrations of HDL after adjustment for important confounding factors. Our findings of increased TC, LDL, TG, and decreased HDL in individuals with DS are similar to 1 previous report by Zamorano et al20 in Chile in 1991. In that study, lipid profiles of 72 children with DS were compared with 66 controls without DS. Children with DS were found to have higher TG, TC, LDL, and lower HDL compared with controls. Weight, BMI, age, and gender were not controlled for in that study. Other studies of lipid and lipoprotein concentrations in individuals with DS have produced varying results ranging from no significant difference in cholesterol, triglycerides, and lipoprotein levels between DS and non-DS groups to reports of increased serum cholesterol, triglycerides and oxidatively modified LDL.48,21 Our study is the first to use exclusively sibling controls to show all measured lipid parameters to be less favorable in the DS group after adjustment for important confounding factors.
Our findings of less favorable lipid profiles in the DS group are also significant in light of a recent study on obesity in children with DS. In that study, the authors concluded that, given the high rates of obesity in children with DS, obesity laboratory assessment protocols for the general pediatric population should also be applied to children with DS.22 Although current DS health supervision guidelines encourage the monitoring of BMI and emphasize education to prevent obesity, there are no specific recommendations for obesity-related laboratory assessment.23
The mechanism by which individuals with DS develop a less favorable lipid profile than their siblings is unclear, but, based on our results, this mechanism does not appear to be explained by overall adiposity, as measured by BMI. Differences observed in lipid profile may be related to fat distribution, but, because the current study was not designed to answer this question, anatomic distribution of fat was not measured. In the general population, increased waist circumference and waist-to-height ratio are associated with an unfavorable lipid profile; however, to our knowledge, no studies of adipose tissue distribution in individuals with DS have been performed. In addition, there is a known association between hypothyroidism and hyperlipidemia, and many individuals with DS have hypothyroidism; however, hypothyroidism requiring treatment was one of the exclusion criteria for this study. In their epidemiological study, Hill et al13 postulated that the excess mortality from cardiovascular disease (CVD) in DS may be related to unrecognized congenital heart defect, increased BMI, and tendency toward diabetes mellitus in persons with DS. However, these conditions were excluded or adjusted for in our study, suggesting that an unfavorable lipid profile may also play a role in the increased CVD mortality of individuals with DS.
Hyperglycemia and insulin resistance are also known to be related to dyslipidemia. Hyperglycemia can cause increased oxidative stress, glycosylation of proteins such as LDL cholesterol (making it more atherogenic), decreased nitric oxide production, and increased coagulability, leading to endothelial injury and increased atherogenic risk.24 In addition, insulin resistance at the level of the adipocyte can increase free fatty acids, and result in increased small, dense LDL cholesterol.25 In a previous publication by our group, we compared obesity-related hormones between the same 2 study groups (children with DS and sibling controls).26 We found no significant difference in glucose (83.4 ± 7.7 mg/dL in the DS group and 80.5 ± 11.0 mg/dL in the sibling group, P = .095) or insulin (10 ± 10.3 μU/mL in DS group vs 7.7 ± 2.2 μU/mL in the sibling group, P = .3) between the 2 groups in the unadjusted comparison. When the comparison was adjusted for age, gender, race, and ethnicity, the difference in insulin was still not significant (P = .1), but the difference in glucose became statistically significant (P = .007). Despite the statistical significance, the authors do not believe the difference between 83.4 mg/dL and 80.5 mg/dL to be clinically significant. They are both well within the normal fasting glucose range. Although the relationship between glucose and the risk for diabetes is considered to be a continuum (even if glucose is in the normal range), the authors do not know of any such data for the relationship between glucose and dyslipidemia.
Given our study design and results, congenital heart defects, hypothyroidism, weight status, glucose, and insulin levels are unlikely to explain the difference in lipid profile in these children with DS compared with their siblings, and the question of whether overexpression of chromosome 21 directly influences lipid profile can be raised. In a study screening for additional familial combined hyperlipidemia genes, a locus conferring susceptibility to elevated apoB levels was identified on chromosome 21.27 A study performed on fetuses with DS was suggestive of abnormalities of lipid metabolism in utero, before other factors could influence lipid levels. DS fetuses were also found to have increased TC and increased apolipoprotein A levels compared with controls.28
Another possible mechanism for increased dyslipidemia in children with DS involves leptin, a hormone secreted by adipose tissue that correlates with percentage of fat mass in humans.29 In a previous study, we found that children with DS had increased leptin levels for percentage of body fat when compared with their siblings, suggesting increased leptin resistance at the same fat level with DS.26 Leptin is also significantly associated with total cholesterol and triglycerides, even after adjusting for BMI.30 Therefore, it is possible that increased leptin resistance in DS may play a role in the lipid profile of the children with DS observed here.
The strengths of this study included the use of biological siblings as a control group, reducing the effect of potential familial and environmental factors, as well as the recruitment bias of healthy controls. The limitations of this study include its relatively small sample size and exclusion of individuals with DS who have comorbid disease, which reduces the generalizability to most children with DS. This design, however, decreased the risk of confounding by these conditions and increased the chances to identify an effect of DS alone. Because there is no national DS registry, our sample of patients with DS does not represent a population-based sample of all persons with DS. We acknowledge the possibility that the families willing to participate in our study may have children with more complex medical needs. We acknowledge the possibility that families willing to participate in our study may have children with more complex medical needs. Additional limitations include the failure to control for blood sugar levels, insulin levels, or hemoglobin A1c because blood sugar, insulin, and hemoglobin A2c can potentially affect lipid levels.
Our findings of unfavorable lipid profiles in young, prepubertal, nonobese children with DS are significant in light of recent epidemiological studies showing increased mortality from ischemic heart disease and CVD in persons with DS. It will be important to conduct long-term surveillance of children with DS to determine whether these differences in lipid profile translate into increased morbidity and mortality from CVD. A scientific statement from the American Heart Association presented guidelines for more aggressive cardiovascular risk management in pediatric patients with conditions associated with increased risk of CVD.31 DS is not included among these conditions. If our findings are confirmed by longitudinal data linking lipid profile with CVD morbidity and mortality among people with DS, they would suggest that children with DS also constitute a group at high risk for dyslipidemia and ischemic heart disease and should be considered for early routine screening and treatment, similar to other children at higher risk. As with other populations, treatment should start with therapeutic lifestyle changes and additional pharmacology therapy as needed. Children with DS constitute a large population at high risk for obesity, diabetes and, based on our data, a less favorable lipid profile, which is an additional risk factor for adult CVD. With the increased life expectancy of individuals with DS and the increasing importance of adult chronic disease in this population, optimal CVD prevention is necessary in children and adults with DS.
Acknowledgments
We acknowledge the support of the National Institutes of Health, the National Down Syndrome Society, and the Clinical and Translational Research Center at The Children’s Hospital of Philadelphia. We are also indebted to the Clinical Nutrition Center at The Children’s Hospital of Philadelphia.
Glossary
CVDcardiovascular disease
DSDown syndrome
GEEgeneralized estimating equations
HDLhigh-density lipoprotein
IDintellectual disability
LDLlow-density lipoprotein
TCtotal cholesterol
TGtriglyceride

Footnotes
The following individual’s have met criteria for authorship as defined in the Pediatrics Author Guidelines: Drs Adelekan, Magge, Shults, Stallings, and Stettler.
FINANCIAL DISCLOSURES: The authors have indicated they have no financial relationships relevant to this article to disclose.
FUNDING: This study was funded by the National Institutes of Health and the Clinical Translational Research Center at The Children’s Hospital of Philadelphia (CTRC grant UL1-RR-024134). It was also supported in part by project T77MC00012 from the Maternal and Child Health Bureau (Title V, Social Security Act), Health Resources and Services Administration, Department of Health and Human Services. Funded by the National Institutes of Health (NIH).
1. Parker SE, Mai CT, Canfield MA, et al. National Birth Defects Prevention Network Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006. Birth Defects Res A Clin Mol Teratol. 2010;88(12):1008–1016. [PubMed]
2. Roizen NJ, Patterson D. Down’s syndrome. Lancet. 2003;361(9365):1281–1289. [PubMed]
3. Glasson EJ, Sullivan SG, Hussain R, Petterson BA, Montgomery PD, Bittles AH. The changing survival profile of people with Down’s syndrome: implications for genetic counselling. Clin Genet. 2002;62(5):390–393. [PubMed]
4. Murdoch JC, Rodger JC, Rao SS, Fletcher CD, Dunnigan MG. Down’s syndrome: an atheroma-free model? BMJ. 1977;2(6081):226–228. [PMC free article] [PubMed]
5. Pueschel SM, Craig WY, Haddow JE. Lipids and lipoproteins in persons with Down’s syndrome. J Intellect Disabil Res. 1992;36(pt 4):365–369. [PubMed]
6. Dörner K, Gaethke AS, Tolksdorf M, Schumann KP, Gustmann H. Cholesterol fractions and triglycerides in children and adults with Down’s syndrome. Clin Chim Acta. 1984;142(3):307–311. [PubMed]
7. Salo MK, Solakivi-Jaakkola T, Kivimäki T, Nikkari T. Plasma lipids and lipoproteins in Down’s syndrome. Scand J Clin Lab Invest. 1979;39(5):485–490. [PubMed]
8. Nishida Y, Akaoka I, Nishizawa T, Maruki M, Maruki K. Hyperlipidaemia in patients with Down’s syndrome. Atherosclerosis. 1977;26(3):369–372. [PubMed]
9. Brattström L, Englund E, Brun A. Does Down syndrome support homocysteine theory of arteriosclerosis? Lancet. 1987;1(8529):391–392. [PubMed]
10. Ylä-Herttuala S, Luoma J, Nikkari T, Kivimäki T. Down’s syndrome and atherosclerosis. Atherosclerosis. 1989;76(2-3):269–272. [PubMed]
11. Chaney RH. Neurogenic atherosclerosis in mentally retarded persons. J Ment Defic Res. 1987;31(pt 3):235–240. [PubMed]
12. Moss TJ, Austin GE. Pre-atherosclerotic lesions in Down syndrome. J Ment Defic Res. 1980;24(2):137–141. [PubMed]
13. Hill DA, Gridley G, Cnattingius S, et al. Mortality and cancer incidence among individuals with Down syndrome. Arch Intern Med. 2003;163(6):705–711. [PubMed]
14. Day SM, Strauss DJ, Shavelle RM, Reynolds RJ. Mortality and causes of death in persons with Down syndrome in California. Dev Med Child Neurol. 2005;47(3):171–176. [PubMed]
15. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. Adv Data. 2000;314(314):1–27. [PubMed]
16. Cameron N. The methods of auxologic anthropometry. In: Falkner F, Tanner JM, editors. , eds. Human Growth. 2nd ed New York, NY: Plenum Press; 1986:3–43.
17. Rosner B, Prineas R, Loggie J, Daniels SR. Percentiles for body mass index in U.S. children 5 to 17 years of age. J Pediatr. 1998;132(2):211–222. [PubMed]
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502. [PubMed]
19. Styles ME, Cole TJ, Dennis J, Preece MA. New cross sectional stature, weight, and head circumference references for Down’s syndrome in the UK and Republic of Ireland. Arch Dis Child. 2002;87(2):104–108. [PMC free article] [PubMed]
20. Zamorano A, Guzmán M, Aspillaga M, Avendaño A, Gatica M. [Concentrations of serum lipids in children with Down’s syndrome]. Arch Biol Med Exp (Santiago). 1991;24(1):49–55. [PubMed]
21. Fulgenzi A, Wasserman K, Corsi MM. Significance of autoantibodies to oxidatively modified LDL in plasma of children with Down syndrome. Clin Chem. 2001;47(6):1135–1137. [PubMed]
22. Murray J, Ryan-Krause P. Obesity in children with Down syndrome: background and recommendations for management. Pediatr Nurs. 2010;36(6):314–319. [PubMed]
23. Bull MJ., Committee on Genetics Health supervision for children with Down syndrome. Pediatrics. 2011;128(2):393–406. [PubMed]
24. Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med. 2003;163(11):1306–1316. [PubMed]
25. Coppack SW, Jensen MD, Miles JM. In vivo regulation of lipolysis in humans. J Lipid Res. 1994;35(2):177–193. [PubMed]
26. Magge SN, O’Neill KL, Shults J, Stallings VA, Stettler N. Leptin levels among prepubertal children with Down syndrome compared with their siblings. J Pediatr. 2008;152(3):321–326. [PMC free article] [PubMed]
27. Pajukanta P, Terwilliger JD, Perola M, et al. Genomewide scan for familial combined hyperlipidemia genes in Finnish families, suggesting multiple susceptibility loci influencing triglyceride, cholesterol, and apolipoprotein B levels. Am J Hum Genet. 1999;64(5):1453–1463. [PubMed]
28. Bocconi L, Nava S, Fogliani R, Nicolini U. Trisomy 21 is associated with hypercholesterolemia during intrauterine life. Am J Obstet Gynecol. 1997;176(3):540–543. [PubMed]
29. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334(5):292–295. [PubMed]
30. Sattar N, Wannamethee G, Sarwar N, et al. Leptin and coronary heart disease: prospective study and systematic review. J Am Coll Cardiol. 2009;53(2):167–175. [PubMed]
31. Kavey RE, Allada V, Daniels SR, et al. American Heart Association Expert Panel on Population and Prevention Science. American Heart Association Council on Cardiovascular Disease in the Young. American Heart Association Council on Epidemiology and Prevention. American Heart Association Council on Nutrition, Physical Activity and Metabolism. American Heart Association Council on High Blood Pressure Research. American Heart Association Council on Cardiovascular Nursing. American Heart Association Council on the Kidney in Heart Disease. Interdisciplinary Working Group on Quality of Care and Outcomes Research Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation. 2006;114(24):2710–2738. [PubMed]
Articles from Pediatrics are provided here courtesy of
American Academy of Pediatrics